Technical Analysis for HBP - Helix BioPharma Corp.

Grade Last Price % Change Price Change
F 0.180 2.86% 0.005
HBP closed down 12.5 percent on Wednesday, April 17, 2024, on 31 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 2.86%
Fell Below 50 DMA Bearish 2.86%
MACD Bearish Centerline Cross Bearish 2.86%
Narrow Range Bar Range Contraction 2.86%
Earnings Movers Other 2.86%
Gapped Down Weakness 2.86%
Crossed Above 50 DMA Bullish -10.00%
MACD Bullish Centerline Cross Bullish -10.00%
Narrow Range Bar Range Contraction -10.00%
Gapped Up Strength -10.00%

   Recent Intraday Alerts

Alert Time
Possible Inside Day 12 days ago
Gap Down Partially Closed 12 days ago
Gapped Down (Partial) 12 days ago
2x Volume Pace 12 days ago
Down 2% 12 days ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Helix BioPharma Corp. Description

Helix BioPharma Corp. is an immuno-oncology company, which specializes in the field of cancer therapy. The Company is developing products for the prevention and treatment of cancer based on its technologies. The Company's product development initiatives are focused primarily on technologies that modulate the tumor microenvironment. The Company's technology platform, DOS47 yielded approximately two drug product candidates, L-DOS47 and vDOS47. L-DOS47 is an antibody protein conjugate where the urease component enzymatically converts naturally occurring urea to ammonia. L-DOS47 is under clinical study for the treatment of non-small cell lung cancer (NSCLC). L-DOS47 has completed preclinical testing and manufacturing development, following which, regulatory approvals are obtained in Poland and the United States to conduct Phase I/II and Phase I clinical studies. V-DOS47 is an antibody DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor (VEGFR2).


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Manufacturing Medicine Pharma Clinic Drug Cancer Drugs Medical Specialties Therapy Oncology Tumor Lung Cancer Treatment Of Cancer Antibody Cancer Immunotherapy Non Small Cell Lung Cancer Product Development Monoclonal Antibodies Treatment Of Non Small Cell Lung Cancer

Is HBP a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 0.26
52 Week Low 0.15
Average Volume 16,156
200-Day Moving Average 0.208
50-Day Moving Average 0.187
20-Day Moving Average 0.185
10-Day Moving Average 0.183
Average True Range 0.013
RSI (14) 44.75
ADX 23.2
+DI 39.773
-DI 40.284
Chandelier Exit (Long, 3 ATRs) 0.173
Chandelier Exit (Short, 3 ATRs) 0.198
Upper Bollinger Bands 0.200
Lower Bollinger Band 0.169
Percent B (%b) 0.19
BandWidth 16.883
MACD Line 0.000
MACD Signal Line -0.001
MACD Histogram 0.0003
Fundamentals Value
Market Cap 23.26 Million
Num Shares 133 Million
EPS -0.07
Price-to-Earnings (P/E) Ratio -2.50
Price-to-Sales 0.00
Price-to-Book 18.60
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.183
Resistance 3 (R3) 0.183 0.182 0.181
Resistance 2 (R2) 0.182 0.180 0.181 0.181
Resistance 1 (R1) 0.178 0.179 0.178 0.178 0.180
Pivot Point 0.177 0.177 0.176 0.176 0.177
Support 1 (S1) 0.173 0.175 0.173 0.173 0.170
Support 2 (S2) 0.172 0.174 0.171 0.169
Support 3 (S3) 0.168 0.172 0.169
Support 4 (S4) 0.168